<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312650</url>
  </required_header>
  <id_info>
    <org_study_id>05-0120</org_study_id>
    <nct_id>NCT00312650</nct_id>
  </id_info>
  <brief_title>Doxil and Gemcitabine in Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women and Infants Hospital of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Women and Infants Hospital of Rhode Island</source>
  <brief_summary>
    <textblock>
      Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One
      of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study
      investigates using a lower dose given more frequently in combination with a second drug
      Gemcitabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the toxicities of Doxil and Gemcitabine given on an every two week
      basis. Our hypothesis is that toxicity will be less than that with standard dosing without
      any negative effect on survival. Patients will also be evaluated with CT scans every 3
      months. Toxicity will be assessed with every cycle of treatment. Treatment will continue
      until toxicity or signs of progression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of hand-foot syndrome</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal doxorubicin and gemcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent platinum resistant ovarian cancer

          -  measurable disease

        Exclusion Criteria:

          -  prior treatment with Doxil or Gemzar

          -  life expectancy &lt;3months

          -  cardiac ejection fraction &lt;50%
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A DiSilvestro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Program in Women's Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women and Infants' Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2006</study_first_submitted>
  <study_first_submitted_qc>April 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2006</study_first_posted>
  <last_update_submitted>January 9, 2015</last_update_submitted>
  <last_update_submitted_qc>January 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <keyword>ovarian cancer</keyword>
  <keyword>recurrent</keyword>
  <keyword>progressive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

